LATEST DISCOUNTS & SALES: PROMOTIONS

Close Notification

Your cart does not contain any items

$281.95

Hardback

Not in-store but you can order this
How long will it take?

QTY:

English
Academic Press Inc
20 February 2019
DNA Repair, Volume 115, the latest release in the Advances in Protein Chemistry and Structural Biology series, provides an overview of current developments in mechanisms underlying DNA repair, their involvement in maintaining chromatin repair, the balance between chromosome breaks repair pathways, tumorigenesis, immune signaling and infection-induced inflammation. Specific chapters cover the Structure and function of the multi-subunit TFIIH with insights into nucleotide excision repair, Chromatin repair: how DNA packaging controls double-strand break repair, Controlling the balance between chromosome breaks repair pathways, The targeting of DNA repair pathways in the era of precision oncology, and much more.

Volume editor:   , , , , , ,
Imprint:   Academic Press Inc
Country of Publication:   United States
Dimensions:   Height: 229mm,  Width: 151mm, 
Weight:   720g
ISBN:   9780128155592
ISBN 10:   0128155590
Pages:   383
Publication Date:  
Audience:   Professional and scholarly ,  Undergraduate
Format:   Hardback
Publisher's Status:   Active
1. DNA repair by photolyasesIbrahim Halil Kavakli, Nuri Ozturk and Seref Gul2. TFIIH: A multi-subunit complex at the cross-roads of transcription and DNA repair Olga Kolesnikova, Laura Radu, and Arnaud Poterszman3. Chromatin control in double strand break repairAnastas Gospodinov and Iva Ugrinova4. Controlling the balance between chromosome break repair pathwaysSonia Jimeno, Fernando Mejías-Navarro, Rosario Prados-Carvajal and Pablo Huertas5. Targeting DNA repair in precision medicineReena Beggs and Eddy S. Yang6. Replication stress: Driver and therapeutic target in genomically instable cancersPepijn M. Schoonen, Sergi Guerrero Llobet and Marcel A.T.M. van Vugt7. Claspin: From replication stress and DNA damage responses to cancer therapyDiana Azenha, Maria Celeste Lopes and Teresa C. Martins8. cAMP-mediated regulation of melanocyte genomic instability: A melanoma-preventive strategyNathaniel C. Holcomb, Robert-Marlo Bautista, Stuart G. Jarrett, Madeline Krentz Gober, Katharine M. Carter and John A. D’Orazio9. Mechanistic link between DNA damage sensing, repairing and signaling factors and immune signalingShibani Mukherjee, Salim Abdisalaam, Souparno Bhattacharya, Kalayarasan Srinivasan, Debapriya Sinha and Aroumougame Asaithamby10. Elucidating the role of interacting residues of the MSH2-MSH6 complex in DNA repair mechanism: A computational approachD. Thirumal Kumar, B. Susmita, E. Judith, J. Priyadharshini Christy, C. George Priya Doss and Hatem Zayed11. A computational model to predict the structural and functional consequences of missense mutations in O6-methylguanine DNA methyltransferaseThirumal Kumar D., Enid Mendonca, J. Priyadharshini Christy, C. George Priya Doss and Hatem Zayed

Rossen Donev received his PhD degree in 1999 from the Institute of Molecular Biology, Bulgarian Academy of Sciences. He did postdoctoral training at Imperial Cancer Research Fund, UK (renamed after the merger with Cancer Research Campaign to Cancer Research UK, London Research Institute) and Cardiff University. In 2007 he was awarded a New Investigator Grant Award from the Medical Research Council (UK) to establish himself as an independent Principle Investigator. In 2010 Dr. Donev was appointed Senior Lecturer at Swansea University. In 2016 Dr. Donev joined MicroPharm Ltd (UK) where currently he is Head of Research. He has published more than 60 research papers, chaired scientific meetings and given invited plenary talks. Rossen Donev has consulted on projects related to development of treatments for neurodevelopmental disorders and cancer therapies. He serves as Editor-in-Chief of the Advances in Protein Chemistry and Structural Biology and on editorial board of several other journals. His research interests include signaling pathways involved in neuropsychiatric disorders and tumor escape from the immune system, and development of therapeutic strategies for their treatment. More recently he has focused on development of immunotherapeutics for non-systemic applications.

See Also